Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: RNA-interference therapeutics - BioMarin

Drug Profile

Research programme: RNA-interference therapeutics - BioMarin

Alternative Names: PRO 052; PRO 055; PRO 105; PRO 135; PRO 289

Latest Information Update: 31 May 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Leiden University
  • Developer BioMarin Nederland
  • Class Antisense oligonucleotides
  • Mechanism of Action Antisense RNA modulators; Dystrophin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy; Huntington's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Duchenne muscular dystrophy; Huntington's disease; Muscular dystrophies; Neuroblastoma; Spinal muscular atrophy

Most Recent Events

  • 29 Sep 2015 US PTAB confirms the priority of claims related to the use of exon 51 antisense oligonucleotides in the US application no. 14/198 992
  • 28 Apr 2015 Prosensa Therapeutics is now called BioMarin Nederland
  • 25 Feb 2015 Prosensa has been acquired by BioMarin Pharmaceutical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top